Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies

Area of Science:

• Oncology
• Nephrology
• Translational Medicine

Background:

• Metastatic renal cell cancer (RCC) has seen significant therapeutic advances, improving patient outcomes.
• These advances have not yet translated to early-stage kidney cancer, where adjuvant treatment options are lacking.
• Current standard care for localized high-risk RCC is primary tumor resection.

Purpose of the Study:

• To review recently completed adjuvant vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) trials in RCC.
• To discuss planned adjuvant immune checkpoint inhibitor trials for localized high-risk kidney cancer.
• To explore potential new treatment options and survival benefits for early-stage RCC patients.

Main Methods:

• Review of reported and ongoing adjuvant VEGFR2 TKI trials in RCC.
• Discussion of planned adjuvant immune checkpoint inhibitor trials.
• Analysis of current treatment standards and future therapeutic directions.

Main Results:

• Adjuvant VEGFR2 TKI trials have been completed, with results reported or pending.
• New adjuvant immune checkpoint inhibitor trials are being planned for localized high-risk RCC.
• These investigations aim to establish novel therapeutic strategies for early-stage kidney cancer.

Conclusions:

• Significant hope exists for new treatment options and improved survival for patients with localized high-risk kidney cancer.
• Adjuvant therapies, including VEGFR2 TKIs and immune checkpoint inhibitors, represent a promising frontier.
• Further research and clinical trials are crucial to realize these advancements in early-stage RCC.